Plain-English translation of NCT06600906 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a specialized MRI scan using hyperpolarized 13C pyruvate can predict how well your pancreatic cancer treatment is working. The medication (hyperpolarized 13C pyruvate) is given by injection before the MRI scan to help doctors see how your tumor is using energy. Researchers hope this new imaging approach will help identify which patients are responding to treatment earlier than traditional scans.
Currently, doctors have to wait weeks or months to see if pancreatic cancer treatment is working using standard CT scans. This medication could help doctors identify treatment response much earlier, allowing them to adjust treatment plans sooner if needed.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the medication and then have specialized MRI scans before starting your cancer treatment and again 4 weeks after treatment begins. Some participants may have an additional scan at 8 weeks. You will also have standard CT scans and regular clinical appointments throughout the study. The study aims to track whether the new MRI results can predict how your cancer responds to treatment.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States